Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem

Annals of Pharmacotherapy

Volumn 41, Issue 6, 2007, Pages 1077-1081

  Nicasio, Anthony M ^a   Quintiliani Jr , Richard ^b,c   DeRyke, C Andrew ^d   Kuti, Joseph L ^a   Nicolau, David P ^a,e  

^a HARTFORD HOSPITAL   (United States)

^b Clinical Research Center   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH HOSPITAL   (United States)

^e Center for Anti Infective Research and Development   (United States)

Author keywords

Meningitis; Meropenem; Serratia marcescens

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG INFUSION; DRUG PENETRATION; EPIDURAL ABSCESS; FEMALE; FOLLOW UP; HUMAN; INTERVERTEBRAL DISK HERNIA; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RELAPSE; SERRATIA MARCESCENS; TREATMENT DURATION; TREATMENT OUTCOME; BACTERIAL MENINGITIS; DRUG ADMINISTRATION; ENTEROBACTER INFECTION; MICROBIOLOGY; MIDDLE AGED;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENINGITIS, BACTERIAL; MIDDLE AGED; SERRATIA INFECTIONS; SERRATIA MARCESCENS; THIENAMYCINS;

EID: 34250184131     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K060     Document Type: Article

References (24)

1. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob 2004;3:1-9.
2. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993;328:21-8.
3. Lu CH, Chang WN, Chuang YC, Chang HW. Gram-negative bacillary meningitis in adult post-neurosurgical patients. Surg Neurol 1999;52: 438-43; discussion 443-4.
4. Rahal JJ, Simberkoff MS. Host defense and antimicrobial therapy in adult gram-negative bacillary meningitis. Ann Intern Med 1982;96:468-74.
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
6. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(suppl 1):S42-50.
7. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;27:1117-27.
8. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004;26:1187-98.
9. Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 2004;24:803-7.
10. Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004;24:1641-5.
11. Grant EM, Kuti JL, Nicolau DP, Nightingale CH, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous infusion piperacillin/ tazobactam program in a large, community, teaching hospital. Pharmacotherapy 2002;22:471-83.
12. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 1996;686:19-26.
13. Hejazi A, Falkiner FR. Serratia marcescens. J Med Microbiol 1997; 46:903-12.
14. Bremer AA, Darouiche RO. Ventriculoperitoneal shunt infection due to Serratia marcescens. J Infect 2005;50:138-41.
15. Huang CR, Lu CH, Chien CC, Chang WN. Protean infectious types and frequent association with neurosurgical procedures in adult Serratia marcescens CNS infections: report of two cases and review of the literature. Clin Neurol Neurosurg 2001;103:171-4.
16. Christensen GD, Korones SB, Reed L, Bulley R, McLaughlin B, Bisno AL. Epidemic Serratia marcescens in a neonatal intensive care unit: importance of the gastrointestinal tract as a reservoir. Infect Control 1982; 3:127-33.
17. Aronin SI. Bacterial meningitis: principles and practical aspects of therapy. Curr Infect Dis Rep 2000;2:337-44.
18. Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-5.
19. Package insert. Merrem (meropenem). Wilmington, DE: AstraZeneca, October 2005.
20. Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994;34:175-9.
21. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-83.
22. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999;13:595-618.
23. Nau R, Lassek C, Kinzig-Schippers M, Thiel A, Prange HW, Sorgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 1998;42:2012-6.
24. Tauber MG, Kunz S, Zak O, Sande MA. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1989;33:418-23.